We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation

By HospiMedica International staff writers
Posted on 16 Sep 2015
A new study concludes that first-line treatment with radiofrequency ablation (RFA) is superior to antiarrhythmic drug therapy (AAD) for reducing atrial fibrillation (AF).

Researchers at Linköping University (Sweden), Aarhus University Hospital (Denmark), and other institutions evaluated the five-year follow-up effects of both treatment modalities on health-related quality of life (HRQoL) and symptom burden in 294 patients, who were randomized to AAD (148 patients) or RFA (146 patients). More...
The primary endpoint was the burden of AF as assessed by seven day Holter recording; secondary endpoints were burden of symptomatic AF, HRQoL assessed via the Short Form-36 (SF-36) questionnaire, and need for additional catheter ablation procedures.

Five year follow up was achieved in 245 (83%) of the patients. The results showed that more patients in the catheter ablation group were free from any AF than those in the AAD group. Remaining AF burden was also significantly lower in the RFA group compared to the AAD group; HRQoL scores at five years, however, did not differ between groups. The results were similar when not compensating for missing Holter recordings. The five-year study results were presented at the European Society of Cardiology (ESC) annual meeting, held during August-September 2015 in London (United Kingdom).

“In clinical practice most doctors choose antiarrhythmic drug therapy for initial treatment of symptomatic atrial fibrillation, and catheter ablation is used for patients who fail drug therapy,” said principal author consultant cardiologist Prof. Jens Cosedis Nielsen, MD, of Aarhus University Hospital. “The findings indicate that first-line treatment with catheter ablation is superior to drug therapy for reducing atrial fibrillation. The choice of first-line treatment strategy still needs to be discussed with individual patients, taking into account their disease burden and risks associated with the different treatment strategies.”

AF occurs when the heart's two upper chambers beat erratically, and can lead to serious adverse events such as thrombi travelling from the heart to obstruct arteries supplying the brain, causing stroke, or other parts of the body causing tissue damage. In one form of the condition, paroxysmal AF, patients have bouts of erratic beats that begin spontaneously and usually last less than a week. While AAD can control the heart rhythm and symptoms of AF, many patients do not respond well to the drugs.

Related Links:

Linköping University
Aarhus University Hospital



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
External Defibrillator
HeartSave Y | YA
Radiology System
Riviera SPV AT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.